Zacks Investment Research upgraded shares of SIGA TECH INC (SIGA) from UNDERPERFORM to NEUTRAL on January 31, 2013, with a target price of $3.00.
SIGA Technologies Inc. is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents and vaccines to fight potential biowarfare pathogens. With broad technology platforms in both vaccines and antibiotics, SIGA's product development programs emphasize the increasingly serious problem of drug resistant bacteria. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses, dengue virus, and the filoviruses.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on SIGA TECH INC (SIGA),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment